House dust mite allergy immunotherapy (ASIT biotech)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameHouse dust mite allergy immunotherapy (ASIT biotech)
Drug Alias Namehdm-ASIT+
ClassificationBiologics > Antigen
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHypersensitivity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAsit Biotech Sa
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAsit Biotech Sa
Active IndicationsN/A
Inactive IndicationsHypersensitivity

Other Information

ATC CodeN/A
Related LinksN/A